Ventricular remodelling: consequences and therapy.
The mammalian left ventricle can change its size and shape in response to a variety of stimuli including loss of tissue and external work. These changes in size and shape, defined as remodelling, are the sum total of a number of processes that involve the myocyte and the interstitial fibrous structures which provide the matrix in which the myocyte functions. The adapted mechanisms which occur are affected by humoral and cellular phenomena and can be modified by pharmacological agents. This paper reviews the remodelling process that occurs in myocardial infarction and heart failure and the effect of various pharmacological agents on this remodelling process.
Sabbah
H N
HN
Department of Medicine, Henry Ford Heart and Vascular Institute, Detroit, Michigan.
Goldstein
S
S
D000222:Adaptation, Physiological; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D005109:Extracellular Matrix / Q000473:pathology; D006352:Heart Ventricles / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000473:pathology; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology
D000806:Angiotensin-Converting Enzyme Inhibitors